{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:05:02Z","timestamp":1791669902206,"version":"4.3.4"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2025-0039_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Delayed puberty and osteoporosis are significant challenges in boys with Duchenne muscular dystrophy (DMD). The current International Care Considerations for DMD recommend bisphosphonate after first fracture and testosterone for delayed puberty from 12\u00a0years. This study aimed to investigate the current clinical practices of clinicians managing osteoporosis and testosterone treatment in\u00a0DMD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2025-0039_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An online survey was circulated to paediatric clinicians involved in the management of bone health and puberty in DMD via patient groups (UK, USA, Italy, Israel).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2025-0039_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 51\/105 (48\u202f%) responses were received. For osteoporosis, vertebral fracture of any grade (86\u202f%) and long bone fracture (67\u202f%) were the most common indications for starting bisphosphonates, with IV zoledronate being the most used agent (86\u202f%). Approaches varied in managing bisphosphonate side effects, and transitioning care to adult specialists. Opinions differed on starting bisphosphonate before fracture. Fourty-nine clinicians managing pubertal disorders reported initiating testosterone for delayed puberty typically between 12 and 14\u00a0years, with majority prescribing intramuscular injections (96\u202f%). Duration of testosterone therapy varied, with some using short-term courses and others continuing until adulthood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2025-0039_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This international survey highlights variability in the management of osteoporosis and delayed puberty in DMD. Recommendations on management of side-effects of IV bisphosphonate, osteoporosis therapy during transition, and longer-term treatment into adulthood is required. There is a need for further guidance on testosterone therapy, particularly in regard to monitoring after discontinuation and the threshold for re-initiation of treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2025-0039","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T05:56:54Z","timestamp":1745474214000},"page":"807-814","source":"Crossref","is-referenced-by-count":4,"title":["The use of bisphosphonate and testosterone in young people with Duchenne muscular dystrophy: an international clinician survey"],"prefix":"10.1515","volume":"38","author":[{"given":"Sarah","family":"McCarrison","sequence":"first","affiliation":[{"name":"3526 Bone, Endocrine & Nutrition Research Group in Glasgow, Human Nutrition, University of Glasgow , Glasgow , UK"},{"name":"Department of Paediatric Endocrinology , Royal Hospital for Children , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Abdelrahman","sequence":"additional","affiliation":[{"name":"3526 Bone, Endocrine & Nutrition Research Group in Glasgow, Human Nutrition, University of Glasgow , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-6320","authenticated-orcid":false,"given":"Justin H.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology , Southampton Children\u2019s Hospital , Southampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talat","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology , Leeds Teaching Hospitals NHS Trust , Leeds , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Padidela","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology , Royal Manchester Children\u2019s Hospital , Manchester , UK"},{"name":"Faculty of Biology, Medicine & Health , University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrinda","family":"Saraff","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology , Birmingham Women\u2019s and Children\u2019s Hospital NHS Foundation Trust , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology , Great North Children\u2019s Hospital , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Choong","family":"Wong","sequence":"additional","affiliation":[{"name":"3526 Bone, Endocrine & Nutrition Research Group in Glasgow, Human Nutrition, University of Glasgow , Glasgow , UK"},{"name":"Department of Paediatric Endocrinology , Royal Hospital for Children , Glasgow , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"2025080412565950841_j_jpem-2025-0039_ref_001","doi-asserted-by":"crossref","unstructured":"Bez Batti Angulski, A, Hosny, N, Cohen, H, Martin, AA, Hahn, D, Bauer, J, et al.. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol 2023;14. https:\/\/doi.org\/10.3389\/fphys.2023.1183101.","DOI":"10.3389\/fphys.2023.1183101"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_002","doi-asserted-by":"crossref","unstructured":"Joseph, S, Wang, C, Bushby, K, Guglieri, M, Horrocks, I, Straub, V, et al.. Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar database. JAMA Neurol 2019;76:701\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.0242.","DOI":"10.1001\/jamaneurol.2019.0242"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_003","doi-asserted-by":"crossref","unstructured":"Crabtree, NJ, Adams, JE, Padidela, R, Shaw, NJ, H\u00f6gler, W, Roper, H, et al.. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen. Bone 2018;116:181\u20136. https:\/\/doi.org\/10.1016\/j.bone.2018.07.019.","DOI":"10.1016\/j.bone.2018.07.019"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_004","doi-asserted-by":"crossref","unstructured":"Birnkrant, DJ, Bushby, K, Bann, CM, Alman, BA, Apkon, SD, Blackwell, A, et al.. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018;17:347\u201361. https:\/\/doi.org\/10.1016\/s1474-4422(18)30025-5.","DOI":"10.1016\/S1474-4422(18)30025-5"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_005","doi-asserted-by":"crossref","unstructured":"Bushby, K, Finkel, R, Birnkrant, DJ, Case, LE, Clemens, PR, Cripe, L, et al.. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177\u201389. https:\/\/doi.org\/10.1016\/s1474-4422(09)70272-8.","DOI":"10.1016\/S1474-4422(09)70272-8"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_006","doi-asserted-by":"crossref","unstructured":"McCarrison, S, Denker, M, Dunne, J, Horrocks, I, McNeilly, J, Joseph, S, et al.. Frequency of delayed puberty in boys with contemporary management of Duchenne muscular dystrophy. J\u00a0Clin Res Pediatr Endocrinol 2024;16:458\u201365. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2024.2024-2-18.","DOI":"10.4274\/jcrpe.galenos.2024.2024-2-18"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_007","doi-asserted-by":"crossref","unstructured":"Birnkrant, DJ, Bushby, K, Bann, CM, Apkon, SD, Blackwell, A, Brumbaugh, D, et al.. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17:251\u201367. https:\/\/doi.org\/10.1016\/s1474-4422(18)30024-3.","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_008","doi-asserted-by":"crossref","unstructured":"Henderson, A, Harley, G, Horrocks, I, Joseph, S, Dunne, J, Pysden, K, et al.. Endocrine and bone monitoring in boys with Duchenne muscular dystrophy; do we adhere to the standards of care? J\u00a0Neuromuscul Dis 2023;10:1143\u20134. https:\/\/doi.org\/10.3233\/jnd-230144.","DOI":"10.3233\/JND-230144"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_009","doi-asserted-by":"crossref","unstructured":"Galetaki, D, Szymczuk, V, Shi, M, Merchant, N. Is endocrine surveillance important in the care of Duchenne Muscular Dystrophy? Results from a national survey to patients and families on endocrine complications. eNeurologicalSci 2024;36:100513. https:\/\/doi.org\/10.1016\/j.ensci.2024.100513.","DOI":"10.1016\/j.ensci.2024.100513"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_010","doi-asserted-by":"crossref","unstructured":"Phung, K, Crabtree, N, Connolly, AM, Furlong, P, Hoffman, EP, Jackowski, SA, et al.. Moving beyond the 2018\u00a0minimum international care considerations for osteoporosis management in Duchenne muscular dystrophy (DMD): meeting report from the 3rd international muscle-bone interactions meeting 7th and 14th november 2022. J\u00a0Neuromuscul Dis 2024;11:233\u201352. https:\/\/doi.org\/10.3233\/jnd-230176.","DOI":"10.3233\/JND-230176"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_011","doi-asserted-by":"crossref","unstructured":"Phung, K, McAdam, L, Ma, J, McMillan, HJ, Jackowski, S, Scharke, M, et al.. Risk factors associated with incident vertebral fractures in steroid-treated males with Duchenne muscular dystrophy. J\u00a0Clin Endocrinol Metab 2024;109:536\u201348. https:\/\/doi.org\/10.1210\/clinem\/dgad435.","DOI":"10.1210\/clinem\/dgad435"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_012","doi-asserted-by":"crossref","unstructured":"Ward, LM, Choudhury, A, Alos, N, Cabral, DA, Rodd, C, Sbrocchi, AM, et al.. Zoledronic acid vs placebo in pediatric glucocorticoid-induced osteoporosis: a randomized, double-blind, phase 3 trial. J\u00a0Clin Endocrinol Metab 2021;106:e5222\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgab458.","DOI":"10.1210\/clinem\/dgab458"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_013","doi-asserted-by":"crossref","unstructured":"Sbrocchi, AM, Rauch, F, Jacob, P, McCormick, A, McMillan, HJ, Matzinger, MA, et al.. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int 2012;23:2703\u201311. https:\/\/doi.org\/10.1007\/s00198-012-1911-3.","DOI":"10.1007\/s00198-012-1911-3"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_014","doi-asserted-by":"crossref","unstructured":"Misof, BM, Roschger, P, McMillan, HJ, Ma, J, Klaushofer, K, Rauch, F, et al.. Histomorphometry and bone matrix mineralization before and after bisphosphonate treatment in boys with Duchenne muscular dystrophy: a paired transiliac biopsy study. J\u00a0Bone Min Res 2016;31:1060\u20139. https:\/\/doi.org\/10.1002\/jbmr.2756.","DOI":"10.1002\/jbmr.2756"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_015","doi-asserted-by":"crossref","unstructured":"Lim, A, Zacharin, M, Pitkin, J, de Valle, K, Ryan, MM, Simm, PJ. Therapeutic options to improve bone health outcomes in Duchenne muscular dystrophy: zoledronic acid and pubertal induction. J\u00a0Paediatr Child Health 2017;53:1247\u20138. https:\/\/doi.org\/10.1111\/jpc.13692.","DOI":"10.1111\/jpc.13692"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_016","doi-asserted-by":"crossref","unstructured":"Ronsley, R, Islam, N, Kang, M, Nadel, H, Reilly, C, Metzger, D, et al.. Effects of bisphosphonate therapy on bone mineral density in boys with Duchenne muscular dystrophy. Clin Med Insights Endocrinol Diabetes 2020;13. https:\/\/doi.org\/10.1177\/1179551420972400.","DOI":"10.1177\/1179551420972400"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_017","doi-asserted-by":"crossref","unstructured":"Zheng, WB, Dai, Y, Hu, J, Zhao, DC, Wang, O, Jiang, Y, et al.. Effects of bisphosphonates on osteoporosis induced by Duchenne muscular dystrophy: a prospective study. Endocr Pract 2020;26:1477\u201385. https:\/\/doi.org\/10.4158\/ep-2020-0073.","DOI":"10.4158\/EP-2020-0073"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_018","doi-asserted-by":"crossref","unstructured":"Zacharin, M, Lim, A, Gryllakis, J, Siafarikas, A, Jefferies, C, Briody, J, et al.. Randomized controlled trial evaluating the use of zoledronic acid in Duchenne muscular dystrophy. J\u00a0Clin Endocrinol Metab 2021;106:2328\u201342. https:\/\/doi.org\/10.1210\/clinem\/dgab302.","DOI":"10.1210\/clinem\/dgab302"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_019","doi-asserted-by":"crossref","unstructured":"Ward, LM, Denker, AE, Porras, A, Shugarts, S, Kline, W, Travers, R, et al.. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J\u00a0Clin Endocrinol Metab 2005;90:4051\u20136. https:\/\/doi.org\/10.1210\/jc.2004-2054.","DOI":"10.1210\/jc.2004-2054"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_020","doi-asserted-by":"crossref","unstructured":"Ward, LM, Rauch, F. Oral bisphosphonates for paediatric osteogenesis imperfecta? Lancet 2013;382:1388\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(13)61531-7.","DOI":"10.1016\/S0140-6736(13)61531-7"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_021","doi-asserted-by":"crossref","unstructured":"Tian, C, Wong, BL, Hornung, L, Khoury, JC, Rybalsky, I, Shellenbarger, KC, et al.. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. Neuromuscul Disord 2020;30:599\u2013610. https:\/\/doi.org\/10.1016\/j.nmd.2020.06.005.","DOI":"10.1016\/j.nmd.2020.06.005"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_022","doi-asserted-by":"crossref","unstructured":"Kumaki, D, Nakamura, Y, Sakai, N, Kosho, T, Nakamura, A, Hirabayashi, S, et al.. Efficacy of denosumab for glucocorticoid-induced osteoporosis in an adolescent patient with Duchenne muscular dystrophy: a case report. JBJS Case Connect 2018;8:e22. https:\/\/doi.org\/10.2106\/jbjs.cc.17.00190.","DOI":"10.2106\/JBJS.CC.17.00190"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_023","doi-asserted-by":"crossref","unstructured":"Hung, C, Mathews, KD, Shibli-Rahhal, A. Effect of denosumab on bone health in adult patients with duchenne\/becker muscular dystrophy: a report of 2 cases. JBJS Case Connect 2022;12. https:\/\/doi.org\/10.2106\/jbjs.cc.21.00664.","DOI":"10.2106\/JBJS.CC.21.00664"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_024","doi-asserted-by":"crossref","unstructured":"Nasomyont, N, Keefe, C, Tian, C, Hornung, L, Khoury, J, Tilden, JC, et al.. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Osteoporos Int 2020;31:2449\u201359. https:\/\/doi.org\/10.1007\/s00198-020-05549-z.","DOI":"10.1007\/s00198-020-05549-z"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_025","doi-asserted-by":"crossref","unstructured":"Catalano, A, Vita, GL, Russo, M, Vita, G, Lasco, A, Morabito, N, et al.. Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report. Osteoporos Int 2016;27:3655\u20139. https:\/\/doi.org\/10.1007\/s00198-016-3761-x.","DOI":"10.1007\/s00198-016-3761-x"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_026","doi-asserted-by":"crossref","unstructured":"Choong Wong, S, Joseph, S, Capaldi, N, Marco, MD, Dunne, J, Guglieri, M, et al.. A survey of the feasibility of developing osteoporosis clinical trials in Duchenne muscular dystrophy: survey of the opinion of young people with Duchenne muscular dystrophy, families and clinicians. Clin Trials 2021;18:39\u201350. https:\/\/doi.org\/10.1177\/1740774520958395.","DOI":"10.1177\/1740774520958395"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_027","doi-asserted-by":"crossref","unstructured":"Chodankar, D. Introduction to real-world evidence studies. Perspect Clin Res 2021;12:171\u20134. https:\/\/doi.org\/10.4103\/picr.picr_62_21.","DOI":"10.4103\/picr.picr_62_21"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_028","doi-asserted-by":"crossref","unstructured":"Wood, CL, Hollingsworth, KG, Hughes, E, Punniyakodi, S, Muni-Lofra, R, Mayhew, A, et al.. Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area. Eur J Endocrinol 2021;184:67\u201379. https:\/\/doi.org\/10.1530\/eje-20-0709.","DOI":"10.1530\/EJE-20-0709"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_029","doi-asserted-by":"crossref","unstructured":"Lee, SL, Lim, A, Munns, C, Simm, PJ, Zacharin, M. Effect of testosterone treatment for delayed puberty in Duchenne muscular dystrophy. Horm Res Paediatr 2020;93:108\u201318. https:\/\/doi.org\/10.1159\/000508290.","DOI":"10.1159\/000508290"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_030","doi-asserted-by":"crossref","unstructured":"Loscalzo, E, See, J, Bharill, S, Yousefzadeh, N, Gough, E, Wu, M, et al.. Growth hormone and testosterone delay vertebral fractures in boys with muscular dystrophy on chronic glucocorticoids. Osteoporos Int 2024;35:327\u201338. https:\/\/doi.org\/10.1007\/s00198-023-06951-z.","DOI":"10.1007\/s00198-023-06951-z"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_031","doi-asserted-by":"crossref","unstructured":"Lucas-Herald, AK, Mason, E, Beaumont, P, Mason, A, Shaikh, MG, Wong, SC, et al.. Single-centre experience of testosterone therapy\u00a0for\u00a0boys with hypogonadism. Horm Res Paediatr 2018;90:123\u20137. https:\/\/doi.org\/10.1159\/000490738.","DOI":"10.1159\/000490738"},{"key":"2025080412565950841_j_jpem-2025-0039_ref_032","doi-asserted-by":"crossref","unstructured":"Wood, CL, Hollingsworth, KG, Bokaie, E, Hughes, E, Muni-Lofra, R, Mayhew, A, et al.. Is ongoing testosterone required after pubertal induction in Duchenne muscular dystrophy? Endocr Connect 2023;12. https:\/\/doi.org\/10.1530\/ec-23-0245.","DOI":"10.1530\/EC-23-0245"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0039\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0039\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T12:57:55Z","timestamp":1754312275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0039\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,5]]},"published-print":{"date-parts":[[2025,8,26]]}},"alternative-id":["10.1515\/jpem-2025-0039"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2025-0039","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}